← Research library / Metabolic

Survodutide: What the Evidence Actually Shows

Strong trial dataInvestigational

Status first

Survodutide is not approved in any country. It is in Phase 3 development. No legal supply exists.

The short version

  • A dual agonist at the GLP-1 and glucagon receptors.
  • Developed by Boehringer Ingelheim with Zealand Pharma.
  • Notable for results in MASH (fatty liver disease) as well as obesity.
  • The glucagon component is the differentiator and also the source of its distinct side effect profile.
  • Investigational. Not available.

The glucagon question

Adding glucagon receptor agonism is counterintuitive, since glucagon raises blood sugar. The rationale is that glucagon also increases energy expenditure and promotes hepatic fat oxidation, and that pairing it with a GLP-1 offsets the glycaemic downside while keeping the metabolic upside. Survodutide and retatrutide both take this approach.

It appears to work, and it is also why the liver disease data has drawn attention. It also means the side effect profile is not identical to a pure GLP-1, which matters for anyone self-administering without monitoring.

What this will not do

Related

Full library · Safety and sourcing · Reconstitution calculator · The 2026 regulatory picture

Regulatory status current as of the page date. This area is changing quickly and this page is reviewed monthly.